A live primary cell phenotypic assay with single-cell resolution can predict postsurgical adverse pathology with >80% accuracy for patients with prostate or breast cancer.
A live primary cell phenotypic assay with single-cell resolution can predict postsurgical adverse pathology with >80% accuracy for patients with prostate or breast cancer.